Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Dabrafenib (Tafinlar) and trametinib (Mekinist) combination therapy for advanced BRAF mutated non-small cell lung cancer. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' objectives Non-small cell lung cancer is the most common type of lung cancer. It is often diagnosed late and is difficult to treat once it has spread to other parts of the body. Cancer cells usually have mutations (abnormal changes) in their DNA when compared to normal cells. BRAF is a rare type of mutation found in a small number of lung cancers.
Dabrafenib and trametinib are two drugs that are being given together for the treatment of non-small cell lung cancer. The drugs are given as two separate tablets that are taken together each day. Some studies have suggested dabrafenib and trametinib may be used as an additional treatment that may be helpful for people who have advanced non-small cell lung cancer with BRAF mutations. Studies are currently ongoing to see how well dabrafenib and trametinib work in combination and how safe they are to use.
If dabrafenib and trametinib are licensed for use in the UK, they could be a new treatment option for patients with advanced non-small cell lung cancer, which may improve survival and cause fewer side effects than current treatments (usually chemotherapy). Indexing Status Subject indexing assigned by CRD MeSH Carcinoma, Non-Small-Cell Lung; Humans; Imidazoles; Oximes; Pyridones; Pyrimidinones Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000632 Date abstract record published 19/04/2016 |